TipRanks

Notifications

Tag: GILD

Total 437 Posts

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and Gilead Sciences (GILD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AbbVie (ABBVResearch Report) and Gilead Sciences (GILDResearch Report).

Gilead Sciences (GILD)

Leerink Partners analyst Daina Graybosch maintained a Hold rating on Gilead Sciences on March 6 and set a price target of $79.00. The company’s shares closed last Friday at $72.61, close to its 52-week low of $71.37.

According to TipRanks.com, Graybosch ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.3% and a 36.4% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Turnstone Biologics Corp., Werewolf Therapeutics, and Century Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gilead Sciences with a $85.78 average price target, implying a 17.3% upside from current levels. In a report issued on February 22, Truist Financial also downgraded the stock to Hold with a $82.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ABBV: